Re: your points:1. Agree2. Nir not # 1 in
Europe...GFX and Duet are. Nir 3rd. If you insist Nir is # 1,
please cite most recent quarter sales figures from
Europe for Nir.3. Will be able to sell Rx in U.S. but
will not be able to sell Rx with hypotube
shaft...patent recently issued to USCI. 4. At one time, yes. Now
no. They have hired many many new people over the
past year or so. If you said best marketing, I'd say
yes.5. Maybe so but what about $2.6 billion in long term
debt?6. P/E is pretty high already, how in the world do
you figure $170?
Look at the fundamentals:
1. BSX is a solid
company with a great pipeline of products, and great
researsh ( especially in Cardio)
2. The NIR (approval
by end of AUGUST) is the #1 selling setnt in
3. Just got all the PATENTS for "rail" technology
4. Best sales force in the
5. All the forward spend happened LAST
Bottom line. BSX is an ABSOLUTE STEAL even at $80/share.
Hop on while you can folks, the BSX train is now
bording for destination $170 by this time next year
here is the article:
Quote, News &
Boston Scientific backs 1998 EPS of $1.90
CHICAGO, July 28 (Reuters) - Medical devices maker Boston
Scientific Corp. on Tuesday provided support for the First
Call 1998 median earnings estimate of $1.90 a share,
compared to $1.66 in 1997. On a conference call with
analysts, Chief Financial Officer Larry Best said, "Our
internal review, division-by-division roll-up, just
completed literally in the last week, those numbers show
that $1.90 is in the ballpark."
Copyright 1998, Reuters News Service
Login / Home / Portfolio Demo / Trading
Demo / Market Monitor
Quotes & News / Research &
Ideas / Customer Service / Site Map
� 1998 DLJdirect Inc. All Rights Reserved. Member
SIPC and NASD. Trademarks of DLJ Long
Copyright � 1996
Reuters Limited. All rights reserved. Republication or
redistribution of Reuters
content is expressly prohibited
without the prior written consent of Reuters. Reuters
shall not be
liable for any errors or delays in the
content, or for any actions taken in reliance thereon.
You forget that the stent approval is already
factored into the price. Went from the 40s to the 70s
after BSX informed analysts of the NIR stent earlier
EPS 0.39, missed it by a penny. This
one is going back to 50.
thanks for your insights. i agree that we will
see a good day when the approval is announced.
however, i think all the talk about splits etc is somewhat
irrational. heartport had a good day when it went from 18 to
30 on the announcement but it is now at 5. as a long
term holder (not a trader) i am more interested in the
numbers as that is all that matters when the music stops.
and.... the numbers here are starting to look a little
scary. best wishes to all bsx holders
Anyone who follows med device companies knows
what will happen when approval hits. Look at historic
Cardima (CRDM) got clearance for pathfinder earlier this
month, goes from 2 � to 11 in one day (closed around
Target Therapeutics, approval for GDC, goes from mid
twenties to over 100 in a few of months (prior to BSX
Heartport (HPRT) receives clearance for system and goes
from 18 to 30 in about a month. (a great example of
the old saying Past performance is no indication of
I believe the same happened for
GDT and their stent release.
Writing�s on the
I am open to listen to disagreements
time for a reality check. the approval of the nir
is already built into the price. we are looking at
over 2 billion in debt (calc the yearly interest on
that) and a pe of 100. i think we will see 60 before 80
but am optomistic for the long term.
Pete told us during a meeting earlier in the year
the split would be in July when the stock hit 90. 2
to 1 was the ratio quoted back then.
latest journey through the plant stated a price of $100
by December. But is that before or after a split?
I'd love to see it split now to 40 and run up to
100!!! But if he said 100....I would guess this means no
split this fall.
Have a great Tuesday!